Science | Page 23 of 29

New Recommendations For Artificial Pancreas Development

A panel of experts convened by the FDA and NIH to try to advance research and development of the artificial pancreas put forth clinical recommendations to ensure the safe and effective testing of artificial pancreas technology in real-life situations. The experts are in agreement that even with the advanced treatments available today...

Cow’s Milk Formula May be Linked to Type 1 Diabetes Risk in Children

A new study has found that keeping babies off cow's milk may help prevent the development of type 1 diabetes in children. The study followed 230 Finnish babies who received formula because breast milk was not available. Half of the babies received standard cow's milk formula...

Diamyd US Phase III Study In Progress

Diamyd Medical announced it has completed the screening of patients for the US Phase III study, DiaPrevent, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age have already been enrolled in the study and have received their first injection of the antigen-based therapy Diamyd or placebo...

Two New Patents Issued to XOMA for Diabetes Drug

The California based bio-tech company XOMA announced that the U.S. Patent and Trademark Office has issued two new patents to XOMA as part of the company's expanding intellectual property portfolio around its XOMA 052 antibody to interleukin-1 beta (IL-1 beta)...

Notes From The Obesity Society Conference 2010

Last month the Obesity Society held its 28th Annual Scientific Meeting, Obesity 2010, in San Diego. A number of prominent researchers, physicians, advocates, and business leaders...

The Frontier of Diabetes Research: An Interview With Dr. Camillo Ricordi

We’re planning a trial in China to block the progression of type 1 at the onset, and see if it’s possible to transplant organs and tissue without the use of lifelong immune suppression drugs...

Eli Lilly Suspends Trials for New Type 1 Diabetes Drug

Eli Lilly and Co. and MacroGenics Inc. announced that the Protege Data Monitoring Committee (DMC), has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab. The DMC, composed of independent experts in the fields of diabetes and biostatistics, concluded that the primary efficacy endpoint of the study was not met...

Can Leptin Improve Blood Sugar Control in Type 1 Diabetics?

A clinical trial at UT Southwestern Medical Center aims to determine whether adding the hormone leptin to standard insulin therapy might help control the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes...

Spherix Inc. Announces Good Results for New Type 2 Diabetes Drug

Spherix Inc., a biotechnology company based in Maryland, announced results of its NEET Phase 3 study of D-tagatose as a monotherapy for type 2 diabetes. The NEET (Naturlose® Efficacy Evaluation Trial) data showed a significant drop in Hemoglobin A1c (HbA1c) levels among patients treated with D-tagatose....

Unraveling the Mystery of the ACCORD Study

John Lachin had one last monkey wrench to throw in. He agreed that the problem was not severe hypoglycemia, and was not rapid lowering of HbA1c...